XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock Based Compensation
9 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock Based Compensation

28. Stock based compensation

The share-based compensation awards issued under the Company’s 2023 Omnibus Incentive Plan to the Company’s employees, officers, directors, are all equity-classified instruments. Restricted stock units ("RSUs") outstanding as of December 31, 2023 have service vesting conditions of one year. Compensation expenses are based on the grant-date fair value of the awards and recognized over the requisite service period using a straight-line method for stock options and a graded vesting method for RSUs. The Company has elected to account for forfeitures of employee stock awards as they occur.

Share-based compensation is in the form of restricted stock units (RSUs). The fair value per RSU is calculated using the Black-Scholes option valuation model.

Option value and assumption

 

 

 

 

 

 

 

 

 

 

 

As of
December 31,
2023

 

Fair value per share (as of grant date)

 

 

 

 

 

 

 

 

 

$

10.83

 

Exercise price

 

 

 

 

 

 

 

 

 

$

0

 

Assumptions:

 

 

 

 

 

 

 

 

 

 

 

Volatility

 

 

 

 

 

 

 

 

 

 

30.82

%

Expected dividends

 

 

 

 

 

 

 

 

 

 

0.00

%

Expected term (in years)

 

 

 

 

 

 

 

 

 

1.5

 

Risk free rate

 

 

 

 

 

 

 

 

 

 

5.24

%

 

Stock option activity

 

 

 

 

 

 

 

 

 

As of
December 31,
2023

 

Opening unvested units

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

 

 

 

 

 

 

 

 

9,903,480

 

Exercised

 

 

 

 

 

 

 

 

 

 

-

 

Cancelled

 

 

 

 

 

 

 

 

 

 

-

 

Closing unvested units

 

 

 

 

 

 

 

 

 

 

9,903,480

 

 

Stock-based compensation expense related to RSUs granted to employees was $27,253,455 for three months ended December 31, 2023. As of December 31, 2023, the unrecognized compensation expense related to unvested RSUs was approximately $76,777,946 which is expected to be recognized over a weighted-average period of approximately 9 months.